Key Publications

Repurposing Pan-HDAC Inhibitors for ARID1A-Mutated Ovarian Cancer. Fukumoto T, Park PH, Wu S, Fatkhutdinov N, Karakashev S, Nacarelli T, Kossenkov AV, Speicher DW, Jean S, Zhang L, Wang TL, Shih IM, Conejo-Garcia JR, Bitler BG, Zhang R. Cell Rep. 2018 Mar 27;22(13):3393-3400. doi: 10.1016/j.celrep.2018.03.019

George E, Kim H, Krepler C, Wenz B, Makvandi M, Tanyi JL, Brown E, Zhang R, Brafford P, Jean S, Mach RH, Lu Y, Mills GB, Herlyn M, Morgan M, Zhang X, Soslow R, Drapkin R, Johnson N, Zheng Y, Cotsarelis G, Nathanson KL, Simpkins F. A patient-derived-xenograft platform to study BRCA-deficient ovarian cancers. JCI Insight. 2017; 2(1):e89760.

Tumor Cell-Independent Estrogen Signaling Drives Disease Progression through Mobilization of Myeloid-Derived Suppressor Cells. Svoronos N, Perales-Puchalt A, Allegrezza MJ, Rutkowski MR, Payne KK, Tesone AJ, Nguyen JM, Curiel TJ, Cadungog MG, Singhal S, Eruslanov EB, Zhang P, Tchou J, Zhang R, Conejo-Garcia JR. Cancer Discov. 2017 Jan;7(1):72-85. doi: 10.1158/2159-8290.CD-16-0502. Epub 2016 Sep 30.

Follicle-Stimulating Hormone Receptor Is Expressed by Most Ovarian Cancer Subtypes and Is a Safe and Effective Immunotherapeutic Target.Perales-Puchalt A, Svoronos N, Rutkowski MR, Allegrezza MJ, Tesone AJ, Payne KK, Wickramasinghe J, Nguyen JM, O’Brien SW, Gumireddy K, Huang Q, Cadungog MG, Connolly DC, Tchou J, Curiel TJ, Conejo-Garcia JR. Clin Cancer Res. 2017 Jan 15;23(2):441-453. doi: 10.1158/1078-0432.CCR-16-0492. Epub 2016 Jul 19.

SATB1 Expression Governs Epigenetic Repression of PD-1 in Tumor-Reactive T Cells. Stephen TL, Payne KK, Chaurio RA, Allegrezza MJ, Zhu H, Perez-Sanz J, Perales-Puchalt A, Nguyen JM, Vara-Ailor AE, Eruslanov EB, Borowsky ME, Zhang R, Laufer TM, Conejo-Garcia JR. Immunity. 2017 Jan 17;46(1):51-64. doi: 10.1016/j.immuni.2016.12.015.

Jean S, Li J, Katsaros D, Wubbenhorst B, Maxwell KN, Fishbein L, Mclane MW, Benedetto C, Canuto E.M., Mitra N, Zhang L, Nathanson KL, Tanyi, JL. Paclitaxel is necessary for improved survival in epithelial ovarian cancers with homologous recombination gene mutations. Oncotarget. 2016 Jul 26;7(30):48577-48585.

Microbially driven TLR5-dependent signaling governs distal malignant progression through tumor-promoting inflammation. Rutkowski MR, Stephen TL, Svoronos N, Allegrezza MJ, Tesone AJ, Perales-Puchalt A, Brencicova E, Escovar-Fadul X, Nguyen JM, Cadungog MG, Zhang R, Salatino M, Tchou J, Rabinovich GA, Conejo-Garcia JR. Cancer Cell. 2015 Jan 12;27(1):27-40. doi: 10.1016/j.ccell.2014.11.009. Epub 2014 Dec 18.

Satb1 Overexpression Drives Tumor-Promoting Activities in Cancer-Associated Dendritic Cells. Tesone AJ, Rutkowski MR, Brencicova E, Svoronos N, Perales-Puchalt A, Stephen TL, Allegrezza MJ, Payne KK, Nguyen JM, Wickramasinghe J, Tchou J, Borowsky ME, Rabinovich GA, Kossenkov AV, Conejo-Garcia JR. Cell Rep. 2016 Feb 23;14(7):1774-1786. doi: 10.1016/j.celrep.2016.01.056. Epub 2016 Feb 11.

Transforming growth factor β-mediated suppression of antitumor T cells requires FoxP1 transcription factor expression. Stephen TL, Rutkowski MR, Allegrezza MJ, Perales-Puchalt A, Tesone AJ, Svoronos N, Nguyen JM, Sarmin F, Borowsky ME, Tchou J, Conejo-Garcia JR. Immunity. 2014 Sep 18;41(3):427-439. doi: 10.1016/j.immuni.2014.08.012.

CLIC1 and CLIC4 complement CA125 as a diagnostic biomarker panel for all subtypes of epithelial ovarian cancer Bipradeb Singha¹, Sandra L. Harper¹, Aaron R Goldman¹, Benjamin G. Bitler², Katherine M. Aird³, Mark E. Borowsky⁴, Mark G. Cadungog⁴, Qin Liu¹, Rugang Zhang⁵, Stephanie Jean⁴, Ronny Drapkin⁶, David W Speicher^1,*
Accepted by Scientific Reports, pending publication.

The N6-methylation of adenosine (m⁶A) in FZD10 mRNA contributes to PARP inhibitor resistance Takeshi Fukumoto ¹, Hengrui Zhu ¹, Sergey Karakashev ¹, Timothy Nacarelli ¹, Nail Fatkhutdinov ^{1, 2}, Shuai Wu ¹, Andrew V. Kossenkov ³, Louise Showe ^3, 4, Stephanie Jean ⁵, Lin Zhang ⁶, Rugang Zhang ^1,. Submitted to Proceedings of the National Academy of Sciences of the United States of America.